BACKGROUND: Infants aged <1 year are at highest risk for pertussis-related morbidity and mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each pregnancy to protect infants in the first months of life; data on effectiveness of this strategy are currently limited. METHODS: We conducted a case-control evaluation among pertussis cases <2 months old with cough onset between 1 January 2011 and 31 December 2014 from 6 US Emerging Infection Program Network states. Controls were hospital-matched and selected by birth certificate. Mothers were interviewed to collect information on demographics, household characteristics, and healthcare providers. Provider-verified immunization history was obtained on mothers and infants. Mothers were considered vaccinated during pregnancy if Tdap was received ≥14 days before delivery; trimester was calculated using Tdap date, infant's date of birth, and gestational age. Odds ratios were calculated using multivariable conditional logistic regression; vaccine effectiveness (VE) was estimated as (1 - odds ratio) × 100%. RESULTS: A total of 240 cases and 535 controls were included; 17 (7.1%) case mothers and 90 (16.8%) control mothers received Tdap during the third trimester of pregnancy. The multivariable VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence interval [CI], 48.3%-90.4%); VE increased to 90.5% (95% CI, 65.2%-97.4%) against hospitalized cases. CONCLUSIONS: Vaccination during pregnancy is an effective way to protect infants during the early months of life. With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptake among pregnant women. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Infants aged <1 year are at highest risk for pertussis-related morbidity and mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each pregnancy to protect infants in the first months of life; data on effectiveness of this strategy are currently limited. METHODS: We conducted a case-control evaluation among pertussis cases <2 months old with cough onset between 1 January 2011 and 31 December 2014 from 6 US Emerging Infection Program Network states. Controls were hospital-matched and selected by birth certificate. Mothers were interviewed to collect information on demographics, household characteristics, and healthcare providers. Provider-verified immunization history was obtained on mothers and infants. Mothers were considered vaccinated during pregnancy if Tdap was received ≥14 days before delivery; trimester was calculated using Tdap date, infant's date of birth, and gestational age. Odds ratios were calculated using multivariable conditional logistic regression; vaccine effectiveness (VE) was estimated as (1 - odds ratio) × 100%. RESULTS: A total of 240 cases and 535 controls were included; 17 (7.1%) case mothers and 90 (16.8%) control mothers received Tdap during the third trimester of pregnancy. The multivariable VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence interval [CI], 48.3%-90.4%); VE increased to 90.5% (95% CI, 65.2%-97.4%) against hospitalized cases. CONCLUSIONS: Vaccination during pregnancy is an effective way to protect infants during the early months of life. With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptake among pregnant women. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Abbey J Hardy-Fairbanks; Stephanie J Pan; Michael D Decker; David R Johnson; David P Greenberg; Kathryn B Kirkland; Elizabeth A Talbot; Henry H Bernstein Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Madison A Naidu; Ruth Muljadi; Miranda L Davies-Tuck; Euan M Wallace; Michelle L Giles Journal: Am J Obstet Gynecol Date: 2016-03-09 Impact factor: 8.661
Authors: Gayatri Amirthalingam; Nick Andrews; Helen Campbell; Sonia Ribeiro; Edna Kara; Katherine Donegan; Norman K Fry; Elizabeth Miller; Mary Ramsay Journal: Lancet Date: 2014-07-15 Impact factor: 79.321
Authors: Karen R Broder; Margaret M Cortese; John K Iskander; Katrina Kretsinger; Barbara A Slade; Kristin H Brown; Christina M Mijalski; Tejpratap Tiwari; Emily J Weston; Amanda C Cohn; Pamela U Srivastava; John S Moran; Benjamin Schwartz; Trudy V Murphy Journal: MMWR Recomm Rep Date: 2006-03-24
Authors: Ha Thi Thu Hoang; Elke Leuridan; Kirsten Maertens; Trung Dac Nguyen; Niel Hens; Ngoc Ha Vu; Raissa Nadège Caboré; Hong Thi Duong; Kris Huygen; Pierre Van Damme; Anh Duc Dang Journal: Vaccine Date: 2015-10-31 Impact factor: 3.641
Authors: Helen E Quinn; Thomas L Snelling; Andrew Habig; Clayton Chiu; Paula J Spokes; Peter B McIntyre Journal: Pediatrics Date: 2014-09-15 Impact factor: 7.124
Authors: Sean T O'Leary; Laura E Riley; Megan C Lindley; Mandy A Allison; Alison P Albert; Allison Fisher; Angela J Jiles; Lori A Crane; Laura P Hurley; Brenda Beaty; Michaela Brtnikova; Allison Kempe Journal: Obstet Gynecol Date: 2019-01 Impact factor: 7.661
Authors: Lourdes R A Vaz-de-Lima; Helena Keico Sato; Eder Gatti Fernandes; Ana Paula Sayuri Sato; Lucia C Pawloski; Maria Lucia Tondella; Cyro A de Brito; Expedito J A Luna; Telma Regina M P Carvalhanas; Euclides A de Castilho Journal: Vaccine Date: 2019-05-29 Impact factor: 3.641
Authors: Sylvia Becker-Dreps; Anne M Butler; Leah J McGrath; Kim A Boggess; David J Weber; Dongmei Li; Michael G Hudgens; J Bradley Layton Journal: Am J Prev Med Date: 2018-06-14 Impact factor: 5.043
Authors: Viviana Romanin; Anna M Acosta; Maria Del Valle Juarez; Elizabeth Briere; Stella Maris Sanchez; Beatriz Lopez Cordoba; Maria Eugenia Sevilla; Maria Florencia Lucion; Anahi Urrutia; Sandra Sagradini; Tami H Skoff; Carla Vizzotti Journal: Clin Infect Dis Date: 2020-01-16 Impact factor: 9.079